Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ORTX Orchard Therapeutics

Watchlist
0.566
-0.034-5.67%
Close  01/27 16:00 ET
0.560
-0.006-1.07%
Post Mkt Price 01/27 17:45 ET
High
0.600
Open
0.580
Turnover
262.40K
Low
0.540
Pre Close
0.600
Volume
463.71K
Market Cap
71.72M
P/E(TTM)
Loss
52wk High
1.230
Shares
126.69M
P/E(Static)
Loss
52wk Low
0.360
Float Cap
40.08M
Bid/Ask %
0.00%
Historical High
21.640
Shs Float
70.80M
Volume Ratio
1.75
Historical Low
0.360
Dividend TTM
--
Div Yield TTM
--
P/B
0.58
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.66%
Amplitude
9.97%
Avg Price
0.565
Lot Size
1
Float Cap
40.08M
Bid/Ask %
0.00%
Historical High
21.640
Shs Float
70.80M
Volume Ratio
1.75
Historical Low
0.360
Dividend TTM
--
P/B
0.58
Dividend LFY
--
Turnover Ratio
0.66%
Amplitude
9.97%
Avg Price
0.565
Lot Size
1
Price Forecast

News

Comment

No Data

Company Overview More
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.
CEO: Dr. Hubert Gaspar
Market: NASDAQ
Listing Date: 10/31/2018
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist